NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Price Target & More

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals announced that its board has approved a share repurchase plan on Thursday, August 10th 2017, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 13.3% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its stock is undervalued.

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) posted its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.53 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.68 by $0.15. The specialty pharmaceutical company had revenue of $46.60 million for the quarter, compared to analysts' expectations of $48.88 million. Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The company's revenue was down 39.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.42 earnings per share. View Eagle Pharmaceuticals' Earnings History.

4 brokerages have issued 1 year price objectives for Eagle Pharmaceuticals' stock. Their forecasts range from $54.00 to $81.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $71.25 in the next twelve months. This suggests that the stock has a possible downside of 14.6%. View Analyst Ratings for Eagle Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Eagle Pharmaceuticals include Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), Evotec (EVTCY), The Medicines (MDCO), Horizon Pharma (HZNP) and Ascendis Pharma A/S (ASND).

News headlines about EGRX stock have trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Eagle Pharmaceuticals earned a news sentiment score of 0.15 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 45.89 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

Eagle Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%), Hartford Investment Management Co. (0.05%), Louisiana State Employees Retirement System (0.02%) and Municipal Employees Retirement System of Michigan (0.02%). Company insiders that own Eagle Pharmaceuticals stock include David Pernock, Douglas L Braunstein, Pete A Meyers, Proquest Investments Iv, LP, Richard A Edlin, Sander A Flaum, Sander A Flaum, Steven B Ratoff and Steven L Krill. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Municipal Employees Retirement System of Michigan. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was purchased by a variety of institutional investors in the last quarter, including Hartford Investment Management Co. and Louisiana State Employees Retirement System. Company insiders that have bought Eagle Pharmaceuticals stock in the last two years include David Pernock, Douglas L Braunstein, Pete A Meyers and Richard A Edlin. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $83.39.

Eagle Pharmaceuticals has a market capitalization of $1.24 billion and generates $236.71 million in revenue each year. The specialty pharmaceutical company earns $51.94 million in net income (profit) each year or $3.37 on an earnings per share basis. Eagle Pharmaceuticals employs 108 workers across the globe.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]